Professor Michael Lisanti
Chair in Translational Medicine
University of Salford
Michael has been an active research scientist for over 30 years, driving research into tumour metabolism and the discovery of novel cancer biomarkers. His current research programme focuses on interactions between the tumour and the host, and repurposing existing drugs as novel cancer therapies.
Fiorillo, M. … Lisanti, M. P. (2016). Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging (Albany, NY) 8(8)
Ozsvari, B. … Lisanti, M. P. (2017). Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. Oncotarget 8(40)